Spruce Biosciences, Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Buybacks vs Stock-Based Comp
Net Debt Issuance
Cash Flow
Cash Flow by Activity
Operating Cash Flow↓-69.1% -$14M
$6M
Free Cash Flow↓-69.1% -$14M
$6M
Investing Cash Flow
$0
Financing Cash Flow
$45M
Capex
$0
Stock-Based Comp↑+76.1% +$731K
$2M
Debt Issued
—
Debt Repaid↑+107.1% +$435K
$841K
D&A↓-44.4% -$4K
$5K
SBC Allocated Expense↑+76.1% +$731K
$2M
SBC Unrecognized Cost
—